Paper Details

  1. Home
  2. Paper Details

A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

Author: HermannsKai, JansenJan-Peter, KleoudisChristi S, LanganJohn, LaskoBen, LorchDaniel, MortensenEric R, PierceAmy, SnidowJerry W, WurzelmannJohn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Alvimopan, a peripherally acting mu-opioid receptor antagonist, was found to be effective in treating opioid-induced constipation (OIC) in a 12-week, double-blind, placebo-controlled trial. In patients receiving opioids for non-cancer pain, the alvimopan 0.5 mg twice-daily group showed a significantly greater proportion of patients experiencing ≥ 3 spontaneous bowel movements (SBMs) per week compared to placebo (72% vs 48%). Alvimopan twice daily also improved other OIC symptoms and reduced the need for rescue laxatives. The treatment was generally well tolerated and did not increase opioid requirements or pain intensity scores.
Paper Details　
Original Abstract of the Article :
Gastrointestinal (GI) side effects are common with opioid medication, and constipation affects ∼40% of patients. Such symptoms considerably impair patients' quality of life. Alvimopan is an orally administered, systemically available, peripherally acting mu-opioid receptor (PAM-OR) antagonist approv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jpain.2010.06.012

データ提供：米国国立医学図書館（NLM）

Alvimopan for Opioid-Induced Bowel Dysfunction: A New Hope for Pain Management

Opioid medications are often used to manage pain, but they can cause significant gastrointestinal side effects, particularly constipation. This study investigates the effectiveness of alvimopan, a medication that blocks opioid receptors in the gut, in treating opioid-induced bowel dysfunction (OIBD).

Alvimopan: A Targeted Approach to Opioid-Induced Constipation

Alvimopan works by specifically blocking opioid receptors in the gut, reducing the constipation associated with opioid use. It's like having a selective filter that allows pain relief while minimizing gastrointestinal side effects. This study found that alvimopan was effective in improving bowel function and reducing constipation in patients receiving opioids for non-cancer pain.

Improving Quality of Life: A More Comfortable Journey

This research suggests that alvimopan could be a valuable tool for managing OIBD, improving the quality of life for patients receiving opioids. It's like finding a smooth road through the desert of opioid-induced constipation, making the journey of pain management more comfortable. However, further research is needed to understand the long-term effects and optimize the use of alvimopan in clinical practice.

Dr.Camel's Conclusion

This study offers hope for a more comfortable and effective approach to managing OIBD. Alvimopan's targeted action in the gut could significantly improve the quality of life for patients receiving opioids, making the journey of pain management smoother and less burdensome. It's like discovering a hidden oasis of comfort in the often-challenging desert of pain management.

Date :
  1. Date Completed 2012-01-09
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

21292169

DOI: Digital Object Identifier

10.1016/j.jpain.2010.06.012

Related Literature

Article Analysis
・Side Effects of alvimopan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.